Skip to main content

Table 1 Clinicopathological features of study population

From: Clinicopathological features, treatment patterns, and prognosis of squamous cell carcinoma of the breast: an NCDB analysis

  Histology P
Infiltrating Ductal Carcinoma Squamous Cell Carcinoma
N %a N %a
Race
 White 2259 83.33 540 79.65 < 0.01
 African American 343 12.65 119 17.55
 Others 109 4.02 19 2.80
 Unknown 33   8   
Charlson-Deyo Score
 0 2346 85.50 555 80.90 0.02
 1 328 11.95 104 15.16
 2 54 1.97 20 2.92
 3 16 0.58 7 1.02
Grade
 I 476 18.90 62 11.33 < 0.01
 II 1058 42.00 151 27.61
 III 985 39.10 334 61.06
 Unknown/IV 225   139   
Lymphovascular Invasion
 Absence 768 79.67 185 85.65 0.04
 Present 196 20.33 31 14.35
 Not Applicable 1780   470   
T-Stage
 T0-T1 1441 52.51 145 21.14 < 0.01
 T2 502 18.29 178 25.95
 T3 67 2.44 100 14.58
 T4 45 1.64 58 8.45
 Tx 689 25.11 205 29.88
N-Stage
 N0 1373 50.04 331 48.25 0.228
 N1 381 13.88 85 12.39
 N2 115 4.19 22 3.21
 N3 56 2.04 16 2.33
 Nx 819 29.85 232 33.82
M-Stage
 M0 2250 82.00 490 71.43 < 0.01
 M1 49 1.79 23 3.35
 Mx 445 16.22 173 25.22
Estrogen Receptor
 Negative 569 21.95 421 74.91 < 0.01
 Positive 2023 78.05 141 25.09
 Unknown 152   124   
Progesterone Receptor
 Negative 843 32.69 491 87.84 < 0.01
 Positive 1736 67.31 68 12.16
 Unknown 165   127   
HER2b
 Negative 829 78.2 207 87.7 < 0.01
 Borderline 31 2.9 2 0.9
 Positive 200 18.9 27 11.4
 Unknown 156   68   
Breast Surgery
 No_Surgery 167 6.10 90 13.16 < 0.01
 Breast-conserving surgery 1561 56.99 246 35.96
 Mastectomy 1010 36.87 348 50.88
 Surgery (Types_Unknown) 1 0.04 0 0.00
 Unknown 5   2   
Radiation Therapy
 No 1119 41.23 373 54.93 < 0.01
 Yes 1595 58.77 306 45.07
 Unknown 30   7   
Chemotherapy
 None 1506 58.28 294 46.08 < 0.01
 Single-Agent Chemotherapy 44 1.70 23 3.61
 Multiagent Chemotherapy 1034 40.02 321 50.31
 Unknown 160   48   
Neoadjuvant chemotherapy
 No 1884 89.89 447 83.86 < 0.01
 Yes 212 10.11 86 16.14
 Unknown 91   14   
Endocrine Therapy
 No 1110 42.53 567 85.91 < 0.01
 Yes 1500 57.47 93 14.09
 Unknown 134   26   
  1. aPercentages were calculated based on the available data
  2. bOnly patients after 2010 were used for analysis of HER2 status
\